Latest

Immunotherapy

Elicio Therapeutics to Present Late-Breaking Data on Immunogenicity and Preclinical Efficacy at SITC Annual Meeting

Elicio Therapeutics, a clinical-stage biotechnology company, announced plans to present late-breaking data on the immunogenicity and preclinical efficacy of its lead product candidate, ELI-002, at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting. The presentation will highlight the promising results from the ongoing Phase 2